港股異動丨基石藥業-B(2616.HK)漲5.61% 又一新藥獲批上市 填補急性髓系白血病精準靶向治療空白
格隆匯2月10日丨基石藥業-B(2616.HK)漲5.61%,報6.4港元,總市值76億港元。基石藥業宣佈,國家藥品監督管理局(NMPA)已批准同類首創藥物拓舒沃(艾伏尼布片)的新藥上市申請。據瞭解,拓舒沃是國內首個獲批的IDH1抑制劑,用於治療攜帶IDH1易感突變的成人復發或難治性急性髓系白血病(R/R AML)患者。這是繼兩款同類首創精準治療藥物普吉華、泰吉華,以及腫瘤免疫治療藥物擇捷美獲批上市後,該公司在一年內成功獲批上市的第四款創新藥。基石藥業方面表示,它的上市將填補急性髓系白血病精準靶向治療的空白,也為公司打開新的治療市場。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.